£16.8m Boost for King's Quantum and Heart Tech Partnerships

King’s College London

Two major King's partnerships have been awarded £16.8 million through London's Local Innovation Partnerships Fund.

Mayor of London, Sadiq Khan, announcing the award of the London's Local Innovation Partnerships Fund at London Life Sciences Week.
Mayor of London, Sadiq Khan, announcing the award of the London's Local Innovation Partnerships Fund at London Life Sciences Week.

Announced this week by the Mayor of London, Sadiq Khan, at London Life Sciences Week, the investment will help translate research in quantum technologies and cardiovascular health into real-world applications.

London's Local Innovation Partnerships Fund, funded by UK Research and Innovation (UKRI), forms part of a wider £500 million national programme to grow high-potential innovation clusters across the UK.

As part of the investment, the London Quantum Cluster will receive £12 million to strengthen the city's position as a global centre for quantum technologies. The partnership, involving King's, UCL and Imperial College London, alongside businesses, investors and public organisations, is pioneering emerging technologies to harness the unusual properties of matter at the smallest scales. The aim is to develop new ways of computing, communicating and sensing, with potential applications in areas including healthcare, transport, finance and security.

A speaker presents to attendees at a London Quantum Cluster event, standing beside a lectern in front of a screen displaying
Credit: Alejandro Salinas Lopez.

Within the programme's challenge-led innovation strand, King's will lead the sector convening for healthcare, and for defence and security, bringing together researchers, businesses and end users to address real-world challenges. Through collaborative projects, businesses will be able to test and refine their technologies, access specialist facilities and industry partnerships, and accelerate product development and progress towards commercial deployment.

Professor James Millen, Co-Director of King's Quantum, King's College London, said: "London is the greatest city in the world to start and grow a quantum business, with access to world-leading scientists and a deep pool of investment. The London Quantum Cluster will help us realise the vision of King's Quantum, driving impact in healthcare, security and defence. Investment in this emerging industry directly impacts university research, creating opportunity, use-cases and valuable pathways to employment for our amazing King's graduates."

A further £5 million will support a partnership between King's and the BioInnovation Institute (BII), also bringing together Imperial College London, University College London (UCL), as well as NHS and industry stakeholders, to establish the Frontier Innovation in Cardiometabolic Disease Venture Builder. Cardiometabolic diseases, including cardiovascular disease, obesity and diabetes, are among the UK's leading causes of ill health and premature death. Despite major advances in research, promising discoveries can struggle to reach patients because researchers often lack the regulatory, commercial and investment expertise needed to develop them into clinical products.

Frontier Innovation in Cardiometabolic Disease Venture Builder launch (L-R): John Craig (UCLPartners), Prof Jenny Shand (UCL), Dr Valentina Vitiello, Prof Sebastien Ourselin (both London Institute for Healthcare Engineering), Louise Clemmenson (BioInnovation Institute) and Dr Nicolas Huber (London Institute for Healthcare Engineering)
Frontier Innovation in Cardiometabolic Disease Venture Builder launch (L-R): John Craig (UCLPartners), Prof Jenny Shand (UCL), Dr Valentina Vitiello, Prof Sebastien Ourselin (both London Institute for Healthcare Engineering), Louise Clemmenson (BioInnovation Institute) and Dr Nicolas Huber (London Institute for Healthcare Engineering)

The five-year programme will combine BII's venture-building expertise in therapeutics with King's research excellence, clinical partnerships and MedTech capabilities, helping researchers develop ventures into viable businesses that help address these health challenges.

Through King's London Institute for Healthcare Engineering (LIHE), up to 25 new ventures will receive support to develop and commercialise medical devices and digital health innovations, drawing on expertise in clinical evaluation, regulatory pathways and MedTech development to attract private investment and create highly skilled jobs.

Professor Sebastien Ourselin FREng FMedSci, Assistant Principal (Innovation) and Director, London Institute for Healthcare Engineering, said: "The Frontier Innovation in Cardiometabolic Disease Venture Builder demonstrates the power of bringing together universities, healthcare providers, innovators, investors and public partners around a shared challenge. London has exceptional strengths in research, clinical care and entrepreneurship, and this investment will help translate that expertise into new ventures, attract further investment and accelerate the development of innovations that improve outcomes for patients with cardiometabolic disease. Together, we have an opportunity to deliver both lasting health impact and sustainable economic growth."

Both the quantum and cardiometabolic programmes will strengthen London's innovation economy, helping new ventures establish and grow in the capital. The investment supports King's Strategy 2030 ambition to foster innovation and entrepreneurship across the university, helping ensure its research delivers benefits for society.

A key part of this ambition is to build innovation clusters around King's campuses, helping companies start, grow and remain in London, connected to the university's research, talent and facilities.

Professor Shitij Kapur, Vice-Chancellor & President of King's College London, said: "The Local Innovation Partnership Fund has been instrumental in enabling this initiative. By combining King's research excellence and facilities with the BioInnovation Institute's venture-building expertise, we can accelerate the translation of discoveries into new therapies and successful businesses, ultimately benefiting patients and society."

The Mayor of London, Sadiq Khan, said: "For centuries, our city has been a beacon of bold ideas and brilliant discoveries. From the discovery of penicillin to groundbreaking research on the structure of DNA, London has helped change the course of modern medicine and saved millions of lives in the process.

"London is one of the most exciting life sciences hubs in the world - thanks to our unique combination of world-leading research, clinical innovation and commercial expertise. But now we want to go even further and make London not just the European capital for life sciences, but the world capital.

"Today, I'm delighted to announce another major step forward. Through the Local Innovation Partnerships Fund, we're providing a new shot in the arm for London's life sciences sector, by investing £22 million into three innovative projects.

"Our commitment has also helped unlock nearly £100 million in match funding, sparking a chain reaction of investment that will create jobs, drive growth and fast-track innovation."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.